Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Unity Biotechnology stock

Own Unity Biotechnology stock in just a few minutes.

Unity Biotechnology, Inc is a biotechnology business based in the US. Unity Biotechnology shares (UBX) are listed on the NASDAQ and all prices are listed in US Dollars. Unity Biotechnology employs 61 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Unity Biotechnology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – UBX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Unity Biotechnology share price

Use our graph to track the performance of UBX stocks over time.

Unity Biotechnology shares at a glance

Information last updated 2021-04-23.
52-week range$2.72 - $12.46
50-day moving average $6.12
200-day moving average $5.81
Wall St. target price$6.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.97

Buy Unity Biotechnology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Unity Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Unity Biotechnology financials

Gross profit TTM $-65,809,000
Return on assets TTM -36.39%
Return on equity TTM -92.19%
Profit margin 0%
Book value $1.56
Market capitalisation $274.6 million

TTM: trailing 12 months

Shorting Unity Biotechnology shares

There are currently 2.0 million Unity Biotechnology shares held short by investors – that's known as Unity Biotechnology's "short interest". This figure is 12.7% down from 2.3 million last month.

There are a few different ways that this level of interest in shorting Unity Biotechnology shares can be evaluated.

Unity Biotechnology's "short interest ratio" (SIR)

Unity Biotechnology's "short interest ratio" (SIR) is the quantity of Unity Biotechnology shares currently shorted divided by the average quantity of Unity Biotechnology shares traded daily (recently around 513701.26582278). Unity Biotechnology's SIR currently stands at 3.95. In other words for every 100,000 Unity Biotechnology shares traded daily on the market, roughly 3950 shares are currently held short.

However Unity Biotechnology's short interest can also be evaluated against the total number of Unity Biotechnology shares, or, against the total number of tradable Unity Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Unity Biotechnology's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Unity Biotechnology shares in existence, roughly 40 shares are currently held short) or 0.0531% of the tradable shares (for every 100,000 tradable Unity Biotechnology shares, roughly 53 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Unity Biotechnology.

Find out more about how you can short Unity Biotechnology stock.

Unity Biotechnology share dividends

We're not expecting Unity Biotechnology to pay a dividend over the next 12 months.

Unity Biotechnology share price volatility

Over the last 12 months, Unity Biotechnology's shares have ranged in value from as little as $2.72 up to $12.46. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Unity Biotechnology's is 0.293. This would suggest that Unity Biotechnology's shares are less volatile than average (for this exchange).

Unity Biotechnology overview

Unity Biotechnology, Inc. , a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site